Kala Pharmaceuticals, Inc. (0JQ2.L)
USD 6.03
(-3.51%)
USD 6.03
(-3.51%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -42.19 Million USD | -18823.32% |
| 2022 | -223 Thousand USD | 99.85% |
| 2021 | -152.29 Million USD | -35.97% |
| 2020 | -112 Million USD | -9.83% |
| 2019 | -101.98 Million USD | -52.81% |
| 2018 | -66.73 Million USD | -58.11% |
| 2017 | -42.21 Million USD | -27.27% |
| 2016 | -33.16 Million USD | -98.82% |
| 2015 | -16.68 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -11.8 Million USD | -36.86% |
| 2024 Q2 | -9.57 Million USD | 18.87% |
| 2023 Q1 | -18.7 Million USD | -34.93% |
| 2023 Q3 | -8.7 Million USD | 16.41% |
| 2023 Q2 | -10.41 Million USD | 44.32% |
| 2023 FY | -42.19 Million USD | -18823.32% |
| 2023 Q4 | -8.62 Million USD | 0.88% |
| 2022 FY | -223 Thousand USD | 99.85% |
| 2022 Q4 | -13.86 Million USD | -147.67% |
| 2022 Q3 | 29.07 Million USD | 206.64% |
| 2022 Q2 | -27.26 Million USD | 17.39% |
| 2022 Q1 | -33 Million USD | 30.62% |
| 2021 Q1 | -30.41 Million USD | 2.25% |
| 2021 Q3 | -28.12 Million USD | 22.94% |
| 2021 Q4 | -47.56 Million USD | -69.12% |
| 2021 Q2 | -36.49 Million USD | -20.01% |
| 2021 FY | -152.29 Million USD | -35.97% |
| 2020 Q2 | -23.31 Million USD | -6.18% |
| 2020 Q4 | -31.11 Million USD | -11.32% |
| 2020 Q1 | -21.95 Million USD | 0.01% |
| 2020 FY | -112 Million USD | -9.83% |
| 2020 Q3 | -27.94 Million USD | -19.89% |
| 2019 Q1 | -25.38 Million USD | -0.67% |
| 2019 FY | -101.98 Million USD | -52.81% |
| 2019 Q4 | -21.95 Million USD | 5.26% |
| 2019 Q3 | -23.17 Million USD | 2.72% |
| 2019 Q2 | -23.82 Million USD | 6.16% |
| 2018 Q2 | -14.62 Million USD | -29.41% |
| 2018 Q1 | -11.29 Million USD | -0.06% |
| 2018 Q3 | -15.6 Million USD | -6.72% |
| 2018 Q4 | -25.21 Million USD | -61.62% |
| 2018 FY | -66.73 Million USD | -58.11% |
| 2017 Q1 | -9.75 Million USD | -16.25% |
| 2017 Q2 | -10.98 Million USD | -12.57% |
| 2017 FY | -42.21 Million USD | -27.27% |
| 2017 Q4 | -11.29 Million USD | -10.96% |
| 2017 Q3 | -10.17 Million USD | 7.38% |
| 2016 Q4 | -8.39 Million USD | 13.16% |
| 2016 Q2 | -9.85 Million USD | -87.6% |
| 2016 Q1 | -5.25 Million USD | 0.0% |
| 2016 Q3 | -9.66 Million USD | 1.89% |
| 2016 FY | -33.16 Million USD | -98.82% |
| 2015 FY | -16.68 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -153.21 Million USD | 72.458% |
| Dynavax Technologies Corporation | -6.38 Million USD | -560.495% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 3306.611% |
| Perrigo Company plc | -12.7 Million USD | -232.276% |
| Illumina, Inc. | -1.16 Billion USD | 96.365% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 100.704% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 90.497% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 99.511% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 103.107% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 61.831% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 101.067% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -5.868% |
| Waters Corporation | 642.23 Million USD | 106.571% |
| Biogen Inc. | 1.16 Billion USD | 103.634% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 83.633% |
| Evolus, Inc. | -61.68 Million USD | 31.59% |
| Adicet Bio, Inc. | -142.65 Million USD | 70.419% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 64.393% |
| bluebird bio, Inc. | -211.91 Million USD | 80.087% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 79.833% |
| FibroGen, Inc. | -284.23 Million USD | 85.153% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 103.403% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 5.39% |
| Homology Medicines, Inc. | -53.74 Million USD | 21.48% |
| Geron Corporation | -184.12 Million USD | 77.082% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 90.415% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 72.161% |
| Myriad Genetics, Inc. | -112 Million USD | 62.322% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 50.871% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 91.23% |
| Zoetis Inc. | 2.34 Billion USD | 101.8% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 22.125% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 105.35% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 125.172% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 101.166% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 88.479% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 84.717% |
| Verastem, Inc. | -87.36 Million USD | 51.699% |
| Nektar Therapeutics | -276.05 Million USD | 84.714% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 82.361% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 52.307% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 92.127% |
| OPKO Health, Inc. | -188.86 Million USD | 77.656% |
| Exelixis, Inc. | 207.76 Million USD | 120.311% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 116.9% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 139.758% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 11.169% |
| uniQure N.V. | -308.47 Million USD | 86.32% |
| Imunon, Inc. | -19.51 Million USD | -116.239% |
| Blueprint Medicines Corporation | -506.98 Million USD | 91.676% |
| Insmed Incorporated | -749.56 Million USD | 94.37% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 114.986% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 88.015% |
| TG Therapeutics, Inc. | 12.67 Million USD | 433.01% |
| Incyte Corporation | 597.59 Million USD | 107.061% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 94.451% |